Wall Street analysts expect PetMed Express, Inc. (NASDAQ:PETS – Get Rating) to announce $0.26 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have made estimates for PetMed Express’ earnings. The lowest EPS estimate is $0.21 and the highest is $0.30. PetMed Express also reported earnings of $0.26 per share during the same quarter last year. The company is expected to issue its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that PetMed Express will report full-year earnings of $1.05 per share for the current financial year, with EPS estimates ranging from $1.04 to $1.05. For the next financial year, analysts forecast that the business will post earnings of $1.09 per share, with EPS estimates ranging from $1.08 to $1.10. Zacks’ earnings per share averages are an average based on a survey of analysts that cover PetMed Express.
PetMed Express (NASDAQ:PETS – Get Rating) last announced its earnings results on Monday, May 9th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.27 by $0.03. PetMed Express had a net margin of 7.72% and a return on equity of 15.45%. The business had revenue of $66.00 million during the quarter, compared to the consensus estimate of $67.80 million. During the same quarter in the previous year, the firm posted $0.34 EPS.
A number of institutional investors have recently added to or reduced their stakes in PETS. Dark Forest Capital Management LP acquired a new position in PetMed Express during the third quarter worth about $33,000. Public Employees Retirement System of Ohio raised its position in PetMed Express by 44.9% during the 4th quarter. Public Employees Retirement System of Ohio now owns 1,546 shares of the company’s stock worth $39,000 after purchasing an additional 479 shares during the last quarter. Captrust Financial Advisors raised its position in shares of PetMed Express by 72.5% during the first quarter. Captrust Financial Advisors now owns 1,570 shares of the company’s stock worth $41,000 after acquiring an additional 660 shares during the last quarter. US Bancorp DE lifted its stake in shares of PetMed Express by 319.1% in the first quarter. US Bancorp DE now owns 3,751 shares of the company’s stock worth $97,000 after acquiring an additional 2,856 shares during the period. Finally, FMR LLC increased its position in PetMed Express by 9,448.1% during the 1st quarter. FMR LLC now owns 5,156 shares of the company’s stock valued at $118,000 after purchasing an additional 5,102 shares during the period. Hedge funds and other institutional investors own 80.95% of the company’s stock.
PETS stock traded up $0.29 during mid-day trading on Thursday, hitting $20.19. 510,499 shares of the company were exchanged, compared to its average volume of 426,162. PetMed Express has a 1-year low of $19.08 and a 1-year high of $46.67. The stock has a market capitalization of $423.57 million, a PE ratio of 19.41 and a beta of 0.55. The business has a 50 day simple moving average of $24.57 and a 200-day simple moving average of $25.93.
The firm also recently announced a quarterly dividend, which will be paid on Friday, May 27th. Shareholders of record on Friday, May 20th will be paid a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 5.94%. The ex-dividend date of this dividend is Thursday, May 19th. PetMed Express’s payout ratio is presently 115.39%.
PetMed Express Company Profile (Get Rating)
PetMed Express, Inc, together with its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Further Reading
- Get a free copy of the StockNews.com research report on PetMed Express (PETS)
- The Institutional Tide Has Turned For Cisco Systems
- Don’t Bet On Cheaper Oil, Not Yet Anway
- Can Nvidia Bounce Back
- A Reversal In The S&P 500 Is Confirmed
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
Get a free copy of the Zacks research report on PetMed Express (PETS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.